

Resource Summary Report

Generated by [dkNET](#) on Aug 13, 2026

E2F-1 Antibody

RRID:AB_2096936

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3742, RRID:AB_2096936

Antibody Information

URL: http://antibodyregistry.org/AB_2096936

Proper Citation: Cell Signaling Technology Cat# 3742, RRID:AB_2096936

Target Antigen: E2F1

Clonality: unknown

Comments: Applications: W, ChIP. Consolidation on 10/2018: AB_10695245, AB_2096936.

Antibody Name: E2F-1 Antibody

Description: This unknown targets E2F1

Target Organism: rat, mouse, human

Antibody ID: AB_2096936

Vendor: Cell Signaling Technology

Catalog Number: 3742

Record Creation Time: 20250819T234939+0000

Record Last Update: 20250820T063237+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 4 is available under ENCODE ID: ENCAB851KCY - ENCODE
<https://www.encodeproject.org/antibodies/ENCAB851KCY>

No alerts have been found for E2F-1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Han S, et al. (2026) Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2/NF- κ B and PI3K/AKT/mTOR pathways in hormone receptor-positive/HER2-negative breast cancer. *Apoptosis : an international journal on programmed cell death*, 31(5).

Goerg A, et al. (2025) Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. *BMC cancer*, 25(1), 978.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. *Cancer cell*.

Paulsohn MB, et al. (2025) Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. *Cell death & disease*, 17(1), 129.

Shah K, et al. (2025) LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression. *Cell reports*, 44(5), 115608.

Jiang X, et al. (2025) KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. *Cell reports. Medicine*, 6(2), 101966.

Malvi P, et al. (2025) PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis. *Cell reports. Medicine*, 6(9), 102356.

Zhen Q, et al. (2025) Erucic Acid, Derived by *Lactobacillus Crispatus*, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR- γ Signaling Pathway. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(48), e12599.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Coleman JC, et al. (2024) The RNA binding proteins LARP4A and LARP4B promote sarcoma and carcinoma growth and metastasis. *iScience*, 27(4), 109288.

Liang J, et al. (2024) Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. *Cell reports*, 43(2), 113771.

Pascual-Pasto G, et al. (2024) Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(16), 3578.

Sicinska E, et al. (2024) ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. *Cancer research*, 84(14), 2247.

Poliaková Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. *Cancer research communications*, 4(7), 1863.

Mouery RD, et al. (2024) Proteomic analysis reveals a PLK1-dependent G2/M degradation program and a role for AKAP2 in coordinating the mitotic cytoskeleton. *Cell reports*, 43(8), 114510.

Yu M, et al. (2023) FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth. *Cell reports*, 42(8), 112886.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

Zhu GQ, et al. (2022) Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma. *Cellular and molecular gastroenterology and hepatology*, 13(5), 1413.

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. *Molecular cell*, 82(18), 3333.